VRTX

518.1500.48%
OT

Ourania Tatsis

Executive VP & Chief Product Affairs Officer

Dr. Ourania Tatsis, also known as Nia, Ph.D., serves as an Independent Director at Odyssey Therapeutics, Inc since September 2025. She was Director of Verve Therapeutics, Inc. from June 2024 to July 25, 2025. Dr. Tatsis has been Executive Vice President and Chief Product Affairs Officer at Vertex Pharmaceuticals Incorporated and served as its Chief Regulatory and Quality Officer since August 2020. Dr. Tatsis was Chief Regulatory Officer at Vertex Pharmaceuticals Incorporated since March 2020 until 2020. Dr. Tatsis was a Senior Vice President at Vertex Pharmaceuticals Incorporated since October 1, 2019 until August 2020 and served as Global Regulatory Affairs from 2020 until March 2020. Dr. Tatsis served as Chief Regulatory Officer at Vertex Pharmaceuticals Incorporated since October 1, 2019 until 2020. Dr. Tatsis served as Senior Vice President of Global Regulatory Affairs at Vertex Pharmaceuticals Incorporated since September 2017 until October 2019. Prior to joining Vertex, Dr. Tatsis held positions of increasing responsibility at pharmaceutical companies such as Sanofi, Stemnion, Pfizer and Wyeth. Most recently, she was Vice President, Head of Global Regulatory Affairs, at the Sanofi Genzyme Business Unit since 2014 until 2017, focused on Inflammation/Immunology, Rare Disease, Multiple Sclerosis, Ophthalmology, Neurology and Oncology/Immuno-Oncology. Dr. Tatsis also worked as an associate staff scientist and research fellow in Immunology and Vaccine Development at the Wistar Institute and completed a post-doctoral research fellowship in Immunology at Thomas Jefferson University. She received her Ph.D. in Cell and Molecular Biology from the University of Vermont and also holds a B. S. in Biology from Temple University.

Positions